Introduction
Major depressive disorder (MDD) is highly prevalent in the general population, with a 12 month prevalence of ~6.7% among U.S. adults (https://www.nimh.nih.gov/health/statistics/major-depression.shtml). The economic burden of MDD in the U.S. was estimated to be $210.5 billion dollars in 2010, a 21.5% increase from 2005 (Greenberg et al., 2015) . The most commonly prescribed treatments for MDD are monoamine reuptake inhibiting antidepressant drugs. However, only about 30% of MDD patients achieve remission after antidepressant treatments according to the findings from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study (Rush et al., 2006) . Researchers have found that multiple factors affect the response to antidepressant treatments, including baseline disease severity , socio-demographic status (Nie et al., 2018; Perlis, 2013) , and biomarker evidence of inflammation (Cattaneo et al., 2016; Cattaneo et al., 2013; Jha et al., 2019; Jha et al., 2017; Powell et al., 2013; Uher et al., 2014) . The latter finding appears particularly relevant to a subset of individuals with MDD who manifest biomarker evidence of inflammation in blood and cerebrospinal fluid (CSF). For example, meta-analysis from studies in the literature confirmed the elevation of C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), soluble interleukin-2 receptor (sIL-2R), IL-10, IL-12, IL-13, IL-18, C-C motif chemokine ligand 2 (CCL2, also known as monocyte chemotactic protein 1 (MCP-1)), IL-1 receptor antagonist, and soluble TNF receptor 2 (sTNF-R2) in MDD patients compared to controls (Dowlati et al., 2010; Haapakoski et al., 2015; Hiles et al., 2012; Howren et al., 2009; Kohler et al., 2017; Liu et al., 2012) , and the Netherlands Study of Depression and Anxiety longitudinal study also suggested that the difference for IL-6 between cases and controls were consistent across longitudinal visits (baseline, year 2, and year 6 follow-up visits) (Lamers et al., 2019) . Meta-analysis also showed that effective antidepressant pharmacotherapy significantly reduced levels of IL-1β, IL-6, IL-4, and CCL2 (Hannestad et al., 2011; Hiles et al., 2012; Kohler et al., 2017; Wiedlocha et al., 2018) . Furthermore, elevation of inflammatory biomarkers at baseline before treatment predicted poorer response to selective serotonin reuptake inhibitor (SSRI) treatment (Cattaneo et al., 2016; Cattaneo et al., 2013; Jha et al., 2019; Jha et al., 2017; Powell et al., 2013; Uher et al., 2014) . Baseline metabolomic profiles also predicted the treatment response to the SSRI, sertraline, and/or to placebo: the predictor of sertraline specific response was 4-hydroxyphenyllactic acid (phenylalanine pathway), the placebo specific response predictor was 5-methoxytryptophol (tryptophan pathway), while dihydroxyphenylacetic acid, gamma tocopherol and serotonin discriminated responders and non-responders to both drug and placebo (Kaddurah-Daouk et al., 2011) .
One mechanism linking inflammation to depressive symptoms involves the enzyme, indoleamine 2,3-dioxygenase (IDO). IDO is activated by proinflammatory cytokines and catalyzes the rate-limiting step in the degradation of the essential amino acid tryptophan (Trp) through the kynurenine (Kyn) pathway, reducing the availability of tryptophan for the synthesis of serotonin and increasing the formation of Kyn and its related neuroactive kynurenine pathway metabolites (Dantzer et al., 2011) . Therefore, the Kyn/Trp ratio putatively is influenced by proinflammatory states. Activation of this pathway involves metabolic conversion of kynurenine to either kynurenic acid (KynA) or 3hydroxykynurenine (3HK) and then quinolinic acid (QuinA). An association between lower plasma levels of Kyn with more severe depression symptoms was reported in MDD patients (Liu et al., 2018) . KynA is hypothesized to be neuroprotective by acting as an antagonist of the NMDA and alpha-7 nicotinic acetylcholine receptors (Stone et al., 2013) , whereas 3HK and QuinA both have shown evidence of exerting neurotoxic effects by their ability to generate oxidative radicals (Block et al., 1993; Guidetti and Schwarcz, 1999; Reus et al., 2015) . Therefore, the KynA/QuinA and KynA/3HK ratios constitute putative neuroprotective indices (Myint et al., 2007; Savitz et al., 2015a) . The KynA/QuinA ratio trended lower in MDD patients versus healthy controls and was correlated negatively with anhedonia but positively with hippocampal and amygdala volumes (Savitz et al., 2015b) . A reduction in the mean KynA/QuinA ratio not only manifests in currently depressed patients, but also in currently remitted MDD subjects relative to healthy controls (Savitz et al., 2015b) . Similarly, KynA/QuinA was significantly lower in the subjects with bipolar disorder compared to healthy controls (Savitz et al., 2015a) . Furthermore, KynA/3HK was also positively associated with hippocampal volume in the patients with bipolar disorder after controlling for age, sex, body mass index (BMI), and intracranial volume (ICV) (Savitz et al., 2015b) .
Previous studies have shown that monoamine reuptake inhibiting antidepressant drugs affect levels of serotonin and kynurenine metabolites.
For example, treatment with sertraline reduced the Kyn/Mel (melatonin) ratio and 3HK/Mel ratio only in MDD patients who responded to sertraline (Zhu et al., 2013) . Another study reported that 24-48 hours of exposure to the SSRIs, fluoxetine and citalopram, or the tricyclic antidepressants, amitriptyline and imipramine, increased the KynA/3HK ratio in astroglial cultures (Kocki et al., 2012) . Significant changes in levels of KynA/QuinA, QuinA/Trp, QuinA/3HK and 3HK/Kyn ratios after 8 weeks and/or 12 weeks treatment with escitalopram was also reported previously (Halaris et al., 2015) . In the current study we investigated the differential relationships between response to the SSRI, escitalopram versus the serotonin and norepinephrine reuptake inhibitor (SNRI), desvenlafaxine, and the baseline plasma levels of serotonin and kynurenine pathway metabolites, and the KynA/QuinA, KynA/3HK, 3HK/Kyn, QuinA/Trp, QuinA/3HK and Kyn/Trp ratios, as well as the treatment-elicited changes. We further examined the correlation of these markers with each other and with depression symptom severity score using baseline pretreatment samples. MDD samples were also compared to healthy control samples despite the sample size for heathy control samples is limited.
Material and Methods

Subjects
Blood was sampled from depressed patients with MDD participating in the Molecular Biomarkers of Antidepressant Response study conducted by McGill University and Douglas Mental Health University Institute. This study included 161 MDD patients 18-65 years of age who underwent 8 weeks of treatment with one of two antidepressant agents, along with 28 healthy controls. Key entrance criteria for the MDD participants were:
1) Diagnosis of current major depressive episode (MDE) of at least moderate severity, as established using the Structured Clinical interview for DSM-V (SCID-I) and HAMD-21 ≥ 20; 2) Current episode duration of no more than 2 years; 3) Absence of comorbid major psychiatric disorders, excepting generalized anxiety disorder, panic disorder, post-traumatic stress disorder and phobias; 4) No history of previous escitalopram treatment for patients included in the escitalopram study arm and no previous history of desvenlafaxine treatment for those included in the desvenlafaxine arm; 5) No comorbid substance disorders and/or recreational drug use, as confirmed by toxicology screens; 6) No use of triptan derivatives; 7) No history of a major general medical condition that requires current pharmacological treatment or affects drug metabolism. In addition, use of an accepted method of contraception was acquired for non-menopausal woman, and pregnant women were excluded. The study design required a 2-week antidepressant washout period prior to initiation of the study treatment (5-weeks for participants using Prozac).
The MDD patients enrolled were randomly assigned to one of two treatment arms: 78 treated with the SSRI, escitalopram; 83 treated with the SNRI, extended release desvenlafaxine (XR). The escitalopram dose started at 10 mg per day for the first week and then could be adjusted following assessments every 2 weeks up to a maximum of 40 mg per day. The desvenlafaxine XR dose started at 50 mg per day and did not need further adjustment. All patients provided written informed consent after receiving a full explanation of the study procedures and risks, as approved by the local Institutional Review Board (IRB).
Serotonin and Kynurenine Pathway Metabolites
Whole blood samples (20-25 mL) were collected into EDTA tubes at pre-treatment baseline and after 8 weeks of treatment. Plasma levels of serotonin (5HT), Tryptophan (Trp), Kynurenine (Kyn), Kynurenic acid (KynA), 3-Hydroxykynurenine (3HK) and Quinolinic acid (QuinA) were measured by Brains Online, LLC (South San Francisco, CA), while blinded to diagnosis and treatment response status. A total of 450 samples were analyzed including baseline, week 8 samples, and week 2 samples (week 2 only collected from a small fraction of study subjects). Only the week 0 and week 8 samples were included in the statistical analysis.
A liquid chromatography-mass spectrometry (LC-MS) assay was used to measure metabolites KYNA, Kyn, 3-HK and Trp. Plasma samples were processed and analyzed by LC-MS/MS using an API 5500 QTRAP detector, run in MRM mode, and a Turbo V Ion Spray interface (AB Sciex, USA).
Plasma samples were mixed with 80% acetonitrile containing an internal standard mixture in a ratio of 1:9 plasma to acetonitrile (v/v). After allowing the proteins to precipitate, the sample was centrifuged, and supernatant was collected and injected onto the HPLC column using an automated sample injector (SIL-20-AC, Shimadzu, Japan). Chromatographic separation was performed on an Atlantis-T3 analytical column (2.1x1500 mm, particle size 3µm, Waters, USA) coupled to a 1290 infinity binary HPLC pump (Agilent, USA) using a linear gradient of acetonitrile in water containing 0.1% formic acid. For each respective analyte, a stable isotopically labelled (SIL) version was used as internal standard.
QuinA was measured by another LC-MS assay. Plasma samples were processed similar to the first LC-MS assay except using an API 4000 detector, and plasma to acetonitrile ratio was 1:4. Chromatographic separation was performed on an Synergi MAX-RP column (100x3mm, particle size 2.5, Phenomenex, USA) coupled to a prominence LC-20AD HPLC pump (Shimadzu, Japan) using a linear gradient of acetonitrile in water containing 0.2% (v/v) TFA (tri fluoric acid).
Serotonin was measured by the SymDaq method using LC-MS assay. Plasma samples were processed and analyzed by LC-MS/MS using an API 4000 detector, run in MRM mode, and a Turbo V Ion Spray interface (AB Sciex, USA). Plasma samples were mixed with cold 0.5M PCA (perchloric acid) in a ratio of 1:4 plasma to PCA (v/v). After allowing the proteins to precipitate, the sample was centrifuged, and supernatant was collected diluted and mixed with an internal standard. The resulting mixture was derivatized on-line with 20 μL SymDaQ reagent and 40 μL was injected into the LC system (Shimadzu prominence series, Shimadzu, Japan) by an automated sample injector (SIL-20ACHT with pretreatment option, Shimadzu, Japan). Chromatographic separation was performed on a Synergi MAX-RP column (100x3mm, particle size 2.5, Phenomenex, USA) coupled to a prominence LC-20AD HPLC pump (Shimadzu, JAPAN) using a linear gradient of acetonitrile in water containing 0.1 % FA.
Data were calibrated and quantified using the ratio on the area of the analyte over their corresponding SIL, using the Analyst data system (ABsciex, version 1.5.2).
Statistical Analysis
Antidepressant treatment outcome was defined using two primary categorical variables (responders vs. non-responders, remitters vs. nonremitters), and one secondary continuous variable (percent improvement in HAMD-21 score from baseline). Responders to antidepressant treatment were defined conventionally based on showing ≥ 50% reduction from baseline in the HAMD-21 score at week 8 (Thase, 2001) .
Remitters were defined conventionally by a week 8 HAMD-21 score of ≤ 7 (Frank et al., 1991) . We used a general linear model to test the association between baseline metabolites levels and the diagnostic status, treatment response status, and percent change in HAMD-21, correcting for age, gender, measurement batch, and baseline HAMD-21 (for treatment response status and percent change in HAMD-21 only) using R 3.5.1. Spearman's rank correlation coefficient between baseline symptom severity score and metabolite levels and among metabolites were also examined. Changes in serotonin and kynurenine pathway metabolites during antidepressant treatment were compared using a mixed model with repeated measures (MMRM) using PROC MIXED (SAS 9.4). To assess the relationship among serotonin and kynurenine pathway metabolites and their ratios as well as baseline HAMD-21 score, Spearman's rank correlation tests were performed. Body mass index (BMI) was also included in the correlation analysis given the relationship between obesity and inflammation. (Varghese et al., 2017) If any of the metabolite of interest was significantly correlated with BMI, the above statistical model would be repeated including BMI as an additional covariate.
Results
Demographic and Clinical Characteristics of the Study Samples
A total of 161 MDD patients and 28 healthy controls participated in this study. Baseline characteristics of the subjects are summarized in Table   1 . On average, the MDD subjects were younger than the healthy controls (mean age of 40.0 ± 12.04 years vs. 46.6 ± 14.51 years, respectively; p = 0.026). There was no significant difference in baseline demographic variables or disease severity between the MDD patients assigned to the two treatment regimens. The Lower Limits of Quantification (LLOQ) and coefficients of variation (CV) for each metabolite assay batch were listed in Supplementary Table S1 . The maximal average CV (across all assay dates for the same metabolite) across all metabolites was less than 8%. Of the 450 samples assayed, only 18 (4.0%), 1 (0.2%), and 3 (0.7%) samples were below the LLOQ for 5HT, KynA, and QuinA, respectively, while no sample was below LLOQ for 3HK, Kyn, and Trp.
After 8 weeks of treatment, the response and remission rates were similar between the MDD patients treated with escitalopram and those treated with desvenlafaxine. Males had numerically higher response and remission rates than females (54.8% vs. 43.4% response rates, and 27.45% vs. 18.2% remission rates, respectively), but these differences were not significant ( Table 2) . Consistent with previous reports (Perlis, 2013) , baseline disease severity was significantly associated with treatment response and remission. Baseline disease severity as measured by the HAMD-21 score was significantly lower in responders in all MDD patients (p = 0.0215) but was not significant in either treatment arm ( Supplementary Figure 1) . Baseline HAMD-21 was also lower in remitters than in non-remitters in all MDD patients (p < 0.0001) and in both treatment arms (p = 0.0014 in escitalopram arm and p=0.0061 in desvenlafaxine arm) ( Table 2 ). The improvement in depressive symptoms after treatment (assessed by percent change in HAMD-21 from baseline) was significantly associated with baseline disease severity in all MDD patients (p = 0.022) and patients treated with escitalopram (p = 0.029), but not in patients treated with desvenlafaxine (p = 0.183).
Plasma Serotonin and Kynurenine Metabolite Levels in the Pre-Treatment Baseline
Plasma serotonin levels were significantly lower in the MDD subjects than in the controls (the LS mean of log10 transformed 5HT levels were 1.74 ± 0.049 and 2.02 ± 0.096, respectively; p = 0.004) ( Figure 1 ). The MDD participants in the escitalopram arm had comparable baseline levels of serotonin compared to those in the desvenlafaxine arm (LS mean of log10 transformed 5HT levels 1.81 ± 0.068 vs. 1.70 ± 0.0561, p = 0.15) (Table1). Raw mean values of the metabolites by diagnosis and by treatment arm are listed in Supplementary Table S2 .
At baseline, none of the individual kynurenine pathway metabolites or metabolite ratios differed significantly between healthy controls and MDD participants or between the two treatment arms (Table 1 ). In the escitalopram arm, the treatment responders showed higher baseline serotonin levels (p = 0.0219), lower Kyn/Trp ratio (p = 0.008) and lower QuinA/Trp ratio (p = 0.047) than non-responders ( Figure 2 , see Supplementary Table S3 for the full list of results). Greater improvement in depression symptoms as measured by percent decrease of HAMD-21 score from baseline was also associated significantly with higher baseline serotonin levels (p = 0.033) and marginally with lower Kyn/Trp ratio (p = 0.096) in escitalopram treated patients ( Supplementary Table S4 ). In the desvenlafaxine treatment arm, none of the baseline levels of individual metabolites or metabolite ratios differed significantly between desvenlafaxine responders and non-responders, nor did they show association with percent improvement in HAMD-21 ( Supplementary Tables S3 and S4 ). Baseline BMI was significantly correlated with Kyn/Trp ratio ( Supplementary Table S5 ). When additionally adjusting for BMI, the findings above were largely unchanged, i.e., in the escitalopram arm, treatment responders showed higher baseline serotonin levels (p = 0.0153), lower Kyn/Trp ratio (p = 0.012) and lower QuinA/Trp ratio (p = 0.0544) than non-responders. Likewise, greater improvement in depression symptoms as measured by percent decrease of HAMD-21 score from baseline was also associated significantly with higher baseline serotonin levels (p = 0.042) and marginally with lower Kyn/Trp ratio (p = 0.077) in escitalopram treated patients.
Baseline metabolite predictors of depression symptom severity score
A small yet significant negative correlation between baseline HAMD-21 score and Kyn levels was observed in MDD patients (Spearman's rank correlation coefficient = -0.16, p = 0.047, Supplementary Table S5 ). All other metabolites or metabolite ratios were not significantly associated with baseline depression severity score HAMD-21.
Changes in Plasma Serotonin and Kynurenine Metabolite Levels During Treatment
After 8 weeks of treatment, plasma serotonin levels were further reduced in both treatment arms (p < 0.0001), but the reduction in the escitalopram arm was significantly greater than that in the desvenlafaxine arm (p = 0.001) (Figure 3 ). Both treatments reduced plasma serotonin levels irrespective of treatment outcome. No significant association was observed between changes in plasma serotonin levels and percent improvement in HAMD-21 after treatment. None of the individual metabolites changed significantly after antidepressant treatment in either arm. In the escitalopram treatment arm, the mean KynA/3HK ratio increased significantly after treatment (p = 0.015 without BMI adjustment, p = 0.012 with BMI adjustment) only in the remitters (Figure 4 ). The ratios of kynurenine metabolites did not differ significantly between responders and non-responders in either treatment regimen.
Discussion
We explored relationships between kynurenine pathway activity in MDD patients receiving treatment with two different antidepressant drugs, by assessing associations between treatment outcome and both baseline kynurenine metabolite levels and treatment associated changes in these metabolites. The mean plasma serotonin levels were reduced in the MDD subjects relative to the healthy controls at baseline and decreased further during treatment with both escitalopram and desvenlafaxine. We also observed an association between lower baseline plasma kynurenine levels and higher HAMD-21 scores in the MDD patients, consistent with a previous report showing that plasma kynurenine concentrations were inversely associated with MDD symptoms severity (Liu et al., 2018) . We did not detect plasma kynurenine metabolite level differences between healthy controls and MDD patients. It is possible that this is due to a smaller effect size for these metabolites relative to serotonin and our study power was limited by the relatively small sample size of the healthy control group. Lower baseline plasma Kyn/Trp and QuinA/Trp ratios and higher baseline serotonin levels were associated with response to escitalopram but not desvenlafaxine. Remitters to escitalopram treatment showed a significant increase in the KynA/3HK ratio, a putative neuroprotective index.
Our finding of an association between lower baseline Kyn/Trp and QuinA/Trp with better escitalopram response appears compatible with a previous report that patients with lower baseline CRP levels had better response to escitalopram (Uher et al., 2014) , since lower Kyn/Trp ratio putatively indicates a lower inflammatory drive on kynurenine pathway activity. Furthermore, relatively higher baseline plasma serotonin levels were associated with better response to the SSRI escitalopram both in our study and in a previous study (Gupta et al., 2016) . In contrast, our results showed that the baseline serotonin level was not associated with clinical response to the SNRI desvenlafaxine, potentially consistent with the direct effect of desvenlafaxine on both serotonin and norepinephrine reuptake, as opposed to escitalopram which directly acts only on serotonin reuptake. The baseline Kyn/Trp and QuinA/Trp ratios were highly correlated with each other (Spearman's rank correlation coefficient = 0.70, p < 0.0001), but the baseline HAMD score, Kyn/Trp ratio and serotonin levels were not significantly correlated ( Supplementary Table S5 ), indicating that their association with treatment response may be independent from each other. Taken together, these results suggest the hypothesis that in MDD a patient's baseline inflammation status and serotonin level hold clinical implications for treatment selection toward a particular antidepressant drug type.
We confirmed the previous report that the baseline plasma kynurenine was negatively associated with depressive symptoms (Liu et al., 2018) .
Interestingly the study went on to identify genetic variants associated with kynurenine level and identified polymorphisms in betadefensin 1 (DEFB1) and aryl hydrocarbon receptor (AHR) genes that were also cis-expression quantitative trait loci (eQTLs) for DEFB1 and AHR mRNA expression. (Liu et al., 2018) Follow up functional genomic experiments confirmed that in vitro recombinant DEFB1 could neutralize lipopolysaccharide(LPS)-stimulated expression of kynurenine biosynthesizing enzyme IDO1 in monocytic cell line and knock down of AHR in a liver cell line resulted in increase of TDO2, KMO, and KYNU mRNA in the kynurenine pathway. (Liu et al., 2018) This study sheds further light into the connection between kynurenine metabolism and immune response using LPS as a paradigm for the innate immune response.
We also found that after 8 weeks of treatment, the plasma serotonin levels decreased further in both treatment arms, although escitalopram treatment induced a greater reduction than desvenlafaxine. A recent study also reported SSRI treatment resulted in a significant reduction in plasma serotonin levels (Gupta et al., 2016) . There are other published studies reporting that SSRI treatment leads to increased plasma serotonin levels, however, which may not be reliable due to small sample size (n = 12) although the same study also reported that serotonin levels in platelets decreased after drug administration (Blardi et al., 2005) . Our observation that higher baseline plasma serotonin level was associated with better response to escitalopram is also consistent with Gupta's study. However, in their study, greater decreases in plasma serotonin lever after 4 and 8 weeks of SSRI treatment was associated with better clinical outcomes, a phenomenon that we did not observe (Gupta et al., 2016) .
Only the MDD subjects who remitted during treatment with escitalopram showed an increase in the KynA/3HK ratio post-treatment. Since the KynA/3HK ratio reflects the ratio between putatively neuroprotective and neurotoxic kynurenine metabolites, respectively (Savitz et al. 2015) , an increase in the KynA/3HK ratio suggests that metabolism in deeper branches of the kynurenine pathway shifts in a more neuroprotective direction under escitalopram treatment. Potentially consistent with this finding, a previous study reported that responders to SSRI showed reduced 3HK/Mel and Kyn/Mel ratios after treatment (Zhu et al., 2013) . Interestingly, exposing astroglial cultures to SSRI or TCA increased the KynA/3HK ratio in the incubation medium in a time-dependent manner: no effect after 2 hours, modest after 24 hours and robust after 48 hours, suggesting that shifting the activity of enzymes deeper in the kynurenine pathway can be induced by SSRI and TCA in brain cells (Kocki et al., 2012) . The observation that this ratio changed only in patients who remitted further suggests the hypothesis that shifting the ratio of these metabolites in the neuroprotective direction is critical for achieving remission during SSRI treatment. Another study reported that treatment with escitalopram changed the KynA/QuinA, QuinA/Trp, QuinA/3HK and 3HK/Kyn ratios after 8 weeks and/or 12 weeks treatment (Halaris et al., 2015) . They did not calculate changes in KynA/3HK ratio in the study. However, their results also suggest that the escitalopram may be able to reduce the synthesis of certain neurotoxic kynurenine metabolites (i.e., QuinA and 3HK) and thus protect the neurons.
The escitalopram and desvenlafaxine XR doses used in this study have produced similar serotonin transporter occupancies (~80%) in PET studies (Frankle et al., 2018; Meyer et al., 2001) . The differences observed in the relationships between serotonin/kynurenine and escitalopram vs. desvenlafaxine thus may reflect the addition of norepinephrine transporter (NET) occupancy by desvenlafaxine. It has been previously reviewed that inflammation impacts motivation and motor activity through its influence on reward processing and dopaminergic corticostriatal circuitry and dopamine plays a role in anhedonia linked to deficiency in reward processing. (Coccurello, 2019; Felger and Treadway, 2017; Gold et al., 2018; Pizzagalli, 2014; Treadway and Zald, 2011) . Symptoms of anhedonia often persist in MDD patients under treatment with SSRI, (Yee et al., 2015) and lower inflammation predicts better treatment response to SSRI (Jha et al., 2019; Jha et al., 2017; Uher et al., 2014) while higher inflammation predicts better response to nortriptyline (like desvenlafaxine, nortriptyline inhibits the reuptake of both serotonin and norepinephrine) (Uher et al., 2014) . Notably, antidepressants that block norepinephrine reuptake also increase dopamine levels as well as norepinephrine in prefrontal cortex and striatal regions that are involved in reward processing, since a substantial amount of dopamine reuptake occurs via NET in these regions (Higashino et al., 2014) . Based on the expectation that the presence of inflammation impairs reward processing, the additional NET inhibition mechanism of desvenlafaxine acts on dopamine and could compensate for the deficit in reward processing partially caused by inflammation, this may explain why only those patients who received escitalopram showed a relationship between baseline Kyn/Trp and/or QuinA/Trp ratios and antidepressant treatment outcome. Notably, a sensitivity to lower tryptophan levels for antidepressants that only inhibit 5HT transporters versus those that inhibit NET also has been reflected in the acute tryptophan depletion (TD) paradigm. Acute TD reverses the remission induced by drugs which preferentially work on serotonergic system such as SSRI antidepressants fluoxetine and fluvoxamine at a greater rate than drugs that potently inhibit norepinephrine reuptake (e.g. desipramine) (Salomon et al., 1993) . These studies also support a potential difference between SSRI and SNRI in relationship to tryptophan availability which is upstream to both serotonin and kynurenine.
In interpreting the reduction of plasma serotonin levels in MDD at baseline, it is noteworthy that most of the serotonin in peripheral blood is synthesized by tryptophan hydroxylase 1 (TPH1) in the enterochromaffin cells of the intestine, which then is secreted into the bloodstream and taken up by circulating platelets. (Walther et al., 2003) Platelets store serotonin at very high concentrations in their dense granules and secrete it upon activation. (McNicol and Israels, 1999) Serotonin cannot pass through brain-blood barrier and therefore the sources of serotonin in the brain and peripheral blood are independent. The current study has the limitation that the serotonin and kynurenine pathway metabolites were measured only in peripheral blood. In experimental animals subjected to chronic mild stress (CMS), a putative animal model of depression-like behaviors, serotonin levels were decreased in the serum, increased in the hippocampus, and unchanged in the cerebral cortex in the CMS group compared to the control group (Wang et al., 2019) suggesting that changes in serotonin levels under CMS do not directly correlate between the blood and the brain, or between different brain regions. In addition, serotonin levels in blood and brain show complex relationships with immune function. For example, serotonin suppresses the release of TNF-α and IL-1β by activating serotonin receptors on monocytes / macrophages, while neutrophil recruitment and T-cell activation can both be mediated by serotonin. (Herr et al., 2017) Moreover, proinflammatory cytokine challenge affects serotonin turnover in the CNS. For example, interferon (IFN)-alpha administration resulted in elevation of CSF IL6 and MCP-1 levels, and the elevation in CSF IL-6 levels was negatively correlated with CSF 5-HIAA levels (the metabolite of 5HT). (Raison et al., 2009 ) Understanding the relationships between immune function and serotonergic function across compartments thus may prove critical to elucidating potential links between peripheral serotonin levels and effects in the brain.
Other limitations of our study design also merit comment. The healthy control sample was relatively small and was modestly older in age than the MDD group. The small sample size reduced the power for detecting potential differences in the kynurenine metabolites between groups.
Moreover, we did not measure cytokines, chemokines, acute phase proteins or other immune biomarkers from the same subjects and therefore could not correlate directly such biomarkers with the kynurenine metabolites.
In summary, by assessing relationships between baseline and treatment-associated changes in plasma metabolite levels in patients treated with different types of antidepressants, we found two independent baseline metabolite biomarkers associated with response to escitalopram but not to desvenlafaxine, and a change in a kynurenine metabolite ratio that appeared specific to remitters to escitalopram. These data suggest that SSRI and SNRI antidepressants are differentially associated with metabolite levels related to kynurenine pathway enzyme activity. Further experiments are warranted to replicate and characterize the specificity of these findings, and to test them in models aimed at predicting treatment outcome.
Conclusions
Our study demonstrated that response to escitalopram treatment was associated with higher baseline serotonin levels and lower baseline Kyn/Trp and QuinA/Trp ratios. Based upon the relationships between these biomarkers and pro-inflammatory signaling our data appear compatible with literature indicating that depressed patients with lower levels of inflammation-related biomarkers are more likely to improve during SSRI treatment. Furthermore, remitters to escitalopram treatment showed significant increases in KynA/3HK ratio, a putative neuroprotective index, 8 weeks after treatment. In contrast, the response to desvenlafaxine treatment was not dependent on baseline concentrations of serotonin or kynurenine pathway metabolites, suggesting that its additional action on catecholamine function broadens its efficacy to extend to depressed patients with inflammation, consistent with previous reports using nortriptyline (Uher et al., 2014) . The magnitude of the reduction in serotonin levels was not associated with either treatment response status (C) or remission status (D), though there was a trend towards responders having greater reduction than non-responders (p= 0.09) 
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